Experienced in Erythema Nodosum

Gal Markel

Petah Tiqwa, M, IL 
Experienced in Erythema Nodosum
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Gal Markel practices in Petah Tiqwa, Israel. Markel is rated as an Experienced expert by MediFind in the treatment of Erythema Nodosum. Their top areas of expertise are Melanoma, Pericarditis, Necrosis, and Erythema Nodosum.

Their clinical research consists of co-authoring 110 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Erythema Nodosum.

Locations

Petah Tiqwa, M, Israel
Other Locations
Tel Aviv, TA, Israel
Tel Litwinsky, TA, Israel
Israel
Ramat Gan, TA 52626, Israel
Ramat Aviv, TA 69978, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pilot Study, Single-Center, Open-Label, Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
A Pilot Study, Single-Center, Open-Label, Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Enrollment Status: Unknown
Publish Date: March 24, 2021
Intervention Type: Combination product
Study Drug: ImmunicomAIAC
Study Phase: Phase 1

110 Total Publications

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation.
Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation.
Journal: Cancer immunology, immunotherapy : CII
Published: March 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Markel's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile